This guideline provides evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other stakeholders.

This algorithm for the comprehensive management of dyslipidemia and prevention of cardiovascular disease (CVD) complements the 2017 AACE Guideline for Management of Dyslipidemia and Prevention of Cardiovascular Disease and provides clinicians with a practical guide that considers the whole patient, their spectrum of risks and complications, and evidence-based approaches to treatment.

This clinical practice guideline provides evidence-based recommendations to reduce the risks and consequences of dyslipidemia. It provides guidance on screening, risk assessment, and treatment recommendations for a range of individuals with various lipid disorders.

Lipodystrophy is a rare, heterogeneous group of syndromes characterized by the complete or partial loss or absence of subcutaneous adipose tissue. This consensus statement provides an overview of the literature and expert opinion on recognizing lipodystrophy and some potential management strategies.

After careful review, AACE may endorse clinical guidance documents developed by external organizations to provide up-to-date recommendations for practice or valuable ancillary knowledge for AACE members and their teams to improve care of patients. Endorsements are reviewed and approved by AACE leadership.